{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T01:53:26Z","timestamp":1788314006346,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003443","name":"Ministry of Education and Science of the Russian Federation","doi-asserted-by":"publisher","award":["075-15-2020-807"],"award-info":[{"award-number":["075-15-2020-807"]}],"id":[{"id":"10.13039\/501100003443","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jtct.2022.11.022","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T12:03:07Z","timestamp":1669377787000},"page":"127.e1-127.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Targeted Therapy With Venetoclax and Daratumumab as Part of HSCT Preparative Regimen in Children With Chemorefractory Acute Myeloid Leukemia"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1216-817X","authenticated-orcid":false,"given":"Maria","family":"Klimentova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa","family":"Shelikhova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Ilushina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Kozlovskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei","family":"Blagov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0889-6986","authenticated-orcid":false,"given":"Alexander","family":"Popov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Kashpor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Fadeeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Olshanskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Glushkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6148-7209","authenticated-orcid":false,"given":"Dmitriy","family":"Pershin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitriy","family":"Balashov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0016-6698","authenticated-orcid":false,"given":"Alexei","family":"Maschan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1735-0093","authenticated-orcid":false,"given":"Michael","family":"Maschan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.11.022_bib0001","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood-2017-04-779769","article-title":"Outcome of children with acute leukemia given HLA-haploidentical HSCT after \u03b1\u03b2 T-cell and B-cell depletion","volume":"130","author":"Locatelli","year":"2017","journal-title":"Blood."},{"key":"10.1016\/j.jtct.2022.11.022_bib0002","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/cncr.30536","article-title":"Allogeneic transplantation for advanced AML: the value of complete remission","volume":"123","author":"Weisdorf","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2022.11.022_bib0003","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1200\/JCO.2010.28.8852","article-title":"Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure","volume":"28","author":"Duval","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2022.11.022_bib0004","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/j.bbmt.2019.01.023","article-title":"\u03b1\u03b2 T cell-depleted haploidentical hematopoietic stem cell transplantation without antithymocyte globulin in children with chemorefractory acute myelogenous leukemia","volume":"25","author":"Shelikhova","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2022.11.022_bib0005","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1038\/s41598-022-05857-w","article-title":"Cell surface expression of GRP78 and CXCR4 is associated with childhood high-risk acute lymphoblastic leukemia at diagnostics","volume":"12","author":"Angeles-Floriano","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtct.2022.11.022_bib0006","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/1024533042000205496","article-title":"Assessment of bcl-2 expression as modulator of fas mediated apoptosis in acute leukemia","volume":"9","author":"Aref","year":"2004","journal-title":"Hematology"},{"key":"10.1016\/j.jtct.2022.11.022_bib0007","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/PAI.0b013e3182606f4d","article-title":"The prognostic value of CXCR4 in acute myeloid leukemia","volume":"21","author":"Ahn","year":"2013","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.jtct.2022.11.022_bib0008","first-page":"98","article-title":"Bcl-2 oncoprotein expression in acute myeloid leukemia","volume":"80","author":"Bensi","year":"1995","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.11.022_bib0009","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0145-2126(99)00147-2","article-title":"Increased CD38 expression is associated with favorable prognosis in adult acute leukemia","volume":"24","author":"Keyhani","year":"2000","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.jtct.2022.11.022_bib0010","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000630","volume":"8","author":"Tembhare","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtct.2022.11.022_bib0011","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","article-title":"Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia","volume":"131","author":"Bride","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.11.022_bib0012","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.bbmt.2019.01.014","article-title":"Mobilization of leukemic cells using plerixafor as part of a myeloablative preparative regimen for patients with acute myelogenous leukemia undergoing allografting: assessment of safety and tolerability","volume":"25","author":"Michelis","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.11.022_bib0013","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/s41409-018-0222-5","article-title":"Daratumumab at the frontiers of post-transplant refractory T-acute lymphoblastic leukemia-a worthwhile strategy?","volume":"53","author":"Bonda","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.11.022_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106442","article-title":"Plerixafor in combination with chemotherapy and\/or hematopoietic cell transplantation to treat acute leukemia: a systematic review and metanalysis of preclinical and clinical studies","volume":"97","author":"Maganti","year":"2020","journal-title":"Leuk Res"},{"key":"10.1016\/j.jtct.2022.11.022_bib0015","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s12185-021-03109-7","article-title":"Phase 1 study of plerixafor in combination with total body irradiation-based myeloablative conditioning for allogeneic hematopoietic stem cell transplantation","volume":"113","author":"Mori","year":"2021","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2022.11.022_bib0016","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1080\/10428194.2021.1966788","article-title":"Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant","volume":"62","author":"Bewersdorf","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2022.11.022_bib0017","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1182\/bloodadvances.2021005566","article-title":"Adding venetoclax to fludarabine\/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active","volume":"5","author":"Garcia","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.jtct.2022.11.022_bib0018","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","article-title":"Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"11","author":"Pullarkat","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtct.2022.11.022_bib0019","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.bbmt.2018.03.006","article-title":"A conditioning regimen with plerixafor is safe and improves the outcome of TCR\u03b1\u03b2\u00a0+\u00a0and CD19\u00a0+\u00a0cell-depleted stem cell transplantation in patients with Wiskott-Aldrich syndrome","volume":"24","author":"Balashov","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10027","key":"10.1016\/j.jtct.2022.11.022_bib0020","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2022.11.022_bib0021","unstructured":"Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825-828."},{"key":"10.1016\/j.jtct.2022.11.022_bib0022","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.bbmt.2014.12.031","article-title":"NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report","volume":"21","author":"Shulman","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.11.022_bib0023","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/s41409-020-01128-2","article-title":"T-cell tracking, safety, and effect of low-dose donor memory T-cell infusions after \u03b1\u03b2 T cell-depleted hematopoietic stem cell transplantation","volume":"56","author":"Blagov","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.11.022_bib0024","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/s41409-017-0035-y","article-title":"Low-dose donor memory T-cell infusion after TCR alpha\/beta depleted unrelated and haploidentical transplantation: results of a pilot trial","volume":"53","author":"Maschan","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.11.022_bib0025","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.bbmt.2018.08.012","article-title":"Kinetics and risk factors of relapse after allogeneic stem cell transplantation in children with leukemia: a long-term follow-up single-center study","volume":"25","author":"Molina","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.11.022_bib0026","doi-asserted-by":"crossref","first-page":"328","DOI":"10.12659\/AOT.915381","article-title":"Outcome and prognostic factors of high-risk acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation","volume":"24","author":"Zhu","year":"2019","journal-title":"Ann Transplant"},{"key":"10.1016\/j.jtct.2022.11.022_bib0027","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1007\/s12185-017-2317-y","article-title":"Risk factors in patients undergoing haploidentical hematopoietic stem cell transplantation for high-risk childhood acute leukemia","volume":"106","author":"Han","year":"2017","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2022.11.022_bib0028","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S1470-2045(20)30060-7","article-title":"Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study","volume":"21","author":"Karol","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2022.11.022_bib0029","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1111\/bjh.16268","article-title":"FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed\/refractory acute leukaemia","volume":"188","author":"Shahswar","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.11.022_bib0030","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3390\/cancers14010150","article-title":"Venetoclax for children and adolescents with acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"14","author":"Gibson","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jtct.2022.11.022_bib0031","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1182\/bloodadvances.2021005566","article-title":"Adding venetoclax to fludarabine\/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active","volume":"5","author":"Garcia","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.11.022_bib0032","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.11.022_bib0033","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1097\/CAD.0000000000001105","article-title":"Successful nelarabine and venetoclax treatment of a relapsed\/refractory mediastinal myeloid sarcoma with clonal TCR rearrangement","volume":"32","author":"Contejean","year":"2021","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.jtct.2022.11.022_bib0034","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00277-019-03902-9","article-title":"Relapsed\/refractory early T-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus HAG regimen","volume":"99","author":"Zhang","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2022.11.022_bib0035","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood.2019000904","article-title":"Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia","volume":"134","author":"Vogiatzi","year":"2019","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.jtct.2022.11.022_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-01300-8","article-title":"Targeting CD38 in acute myeloid leukemia interferes with leukemia trafficking and induces phagocytosis","volume":"11","author":"Farber","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtct.2022.11.022_bib0037","first-page":"41","article-title":"Expression of activation antigens CD38 and CD71 is not clinically important in childhood acute lymphoblastic leukemia","volume":"7","author":"Koehler","year":"1993","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.11.022_bib0038","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/bmt.2015.58","article-title":"Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation","volume":"50","author":"Konopleva","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2022.11.022_bib0039","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13061292","article-title":"Targeting BCL-2 in cancer: advances, challenges, and perspectives","volume":"13","author":"Hafezi","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jtct.2022.11.022_bib0040","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","article-title":"Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma","volume":"1","author":"Casneuf","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.11.022_bib0041","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1158\/1078-0432.CCR-17-3117","article-title":"Fratricide of NK cells in daratumumab therapy for multiple myeloma overcome by ex vivo expanded autologous NK cells","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2022.11.022_bib0042","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3390\/cells9030768","article-title":"NK cells and CD38: implication for (immuno)therapy in plasma cell dyscrasias","volume":"9","author":"Zambello","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jtct.2022.11.022_bib0043","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol"},{"issue":"Suppl 2","key":"10.1016\/j.jtct.2022.11.022_bib0044","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1038\/bmt.2015.87","article-title":"Improved immune recovery after transplantation of TCR\u03b1\u03b2\/CD19-depleted allografts from haploidentical donors in pediatric patients","volume":"50","author":"Lang","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.11.022_bib0045","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1182\/blood-2015-12-629055","article-title":"Exploitation of natural killer cells for the treatment of acute leukemia","volume":"127","author":"Handgretinger","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.jtct.2022.11.022_bib0046","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1080\/14653240701644000","article-title":"A large-scale method for the selective depletion of alphabeta T lymphocytes from PBSC for allogeneic transplantation","volume":"9","author":"Chaleff","year":"2007","journal-title":"Cytotherapy"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722017882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722017882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:09:45Z","timestamp":1763003385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722017882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S2666636722017882"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.11.022","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted Therapy With Venetoclax and Daratumumab as Part of HSCT Preparative Regimen in Children With Chemorefractory Acute Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.11.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}